A study of unprecedented scale has led researchers to identify four previously unknown genetic risk locations for primary sclerosing cholangitis, a liver disease that lacks effective medical therapy. An article in Nature Genetics highlights the undertaking, which is the largest genome-wide association study of primary sclerosing cholangitis to date and a step toward providing breakthrough treatments for the unmet needs of primary sclerosing cholangitis patients.

In a recent Science Advances article, Mayo Clinic researchers show how hungry human liver cells find energy. This study, done in rat and human liver cells, reports on the role of a small regulatory protein that acts like a beacon to help cells locate lipids and provides new information to support the development of therapies for fatty liver disease.

Inherited pathogenic variants in protein coding genes BARD1 and RAD51D increase a woman’s likelihood of developing breast cancer, according to research conducted at Mayo Clinic and presented today at the 2016 San Antonio Breast Cancer Symposium. Pathogenic variants are changes in DNA that have a negative impact on a gene’s ability to function properly.

Researchers at Mayo Clinic Center for Individualized Medicine have discovered a potential cause and a promising new treatment for inflammatory myofibroblastic tumors, a rare soft tissue cancer that does not respond to radiation or chemotherapy.

Research from Mayo Clinic included in the November issue of JAMA Neurology identifies a new biomarker for brain and spinal cord inflammation, allowing for faster diagnosis and treatment of patients.

Research from Mayo Clinic included in the November issue of JAMA Neurology identifies a new biomarker for brain and spinal cord inflammation, allowing for faster diagnosis and treatment of patients.